Imagine your body is like a garden where good and bad bacteria live together. A severe lung infection like pneumonia acts like a storm that disrupts this balance, which can unexpectedly trigger heart problems later on. This work uses AI to spot the warning signs in that bacterial balance to predict and treat heart risks before they happen.
Patients recovering from pneumonia face an increased risk of cardiovascular diseases, but doctors lack the tools to identify who is at risk or how to treat the underlying cause.
The project is building AI algorithms for risk prediction, a set of biomarkers, and preclinical treatments validated up to TRL4.
If you are a drug discovery firm dealing with a lack of targeted therapies for post-infection recovery — this project developed preclinical treatments at TRL4 that target host-microbiome interactions to prevent cardiovascular disease progression.
If you are an AI Health-Tech developer dealing with imprecise patient risk stratification — this project developed AI algorithms that link microbiome data to cardiovascular outcomes to enable early identification of at-risk patients.
If you are a private hospital group dealing with high readmission rates for heart failure after pneumonia — this project developed biomarkers and evidence-based protocols to improve long-term patient recovery and reduce infection burden.
Based on available project data, no pricing or cost information for the AI algorithms is provided.
The project is currently in the preclinical development phase, aiming for TRL4, meaning it is not yet ready for industrial scale.
Based on available project data, specific IP or licensing terms are not mentioned, though the project aims to deliver biomarkers and preclinical treatments.
The project includes a prospective 3-year follow-up for pneumonia survivors and matched controls to compare cardiovascular disease rates.
Based on available project data, the project focuses on developing the algorithms; specific integration protocols for hospital systems are not detailed.
The consortium is heavily research-oriented, consisting of 11 partners across 6 countries. It is composed of 6 universities and 5 research institutions, with only 1 SME and 0 large industry partners. This indicates a high-science, low-commercialization setup, focusing on discovery and preclinical validation rather than immediate market entry.
Contact NANTES UNIVERSITE regarding the Homi-lung project coordination.
Contact SciTransfer for a detailed analysis of the TRL4 treatment pipeline.
